Côme Lepage
YOU?
Author Swipe
View article: Association between induced organ atrophy assessed by artificial intelligence-generated automatic segmentation and efficacy of bevacizumab in combination with chemotherapy in metastatic colorectal cancer
Association between induced organ atrophy assessed by artificial intelligence-generated automatic segmentation and efficacy of bevacizumab in combination with chemotherapy in metastatic colorectal cancer Open
Our findings support the feasibility and reliability of AI in organ volume measurement. While bevacizumab exposure was linked to non-tumoural liver atrophy, its impact on survival remains inconclusive after adjustment. These results pave t…
View article: Epidemiological Classification Changes and Incidence of Early-Onset Colorectal Cancer
Epidemiological Classification Changes and Incidence of Early-Onset Colorectal Cancer Open
Importance Previous studies showed an increasing incidence of early-onset colorectal cancer (EOCRC) during a period when cancer registration guidelines were changed. None of these studies simultaneously compared the patterns in colorectal …
View article: Accounting for Misclassification of Binary Outcomes in External Control Arm Studies for Unanchored Indirect Comparisons: Simulations and Applied Example
Accounting for Misclassification of Binary Outcomes in External Control Arm Studies for Unanchored Indirect Comparisons: Simulations and Applied Example Open
Single‐arm control trials are increasingly proposed as a potential approach for treatment evaluation. However, the limitations of this design restrict its methodological acceptability. Regulatory agencies have raised concerns about this ap…
View article: Nal-IRI/LV5-FU versus paclitaxel as second-line therapy in patients with metastatic esophageal squamous cell carcinoma (PRODIGE 62-FFCD 1701-OESIRI)
Nal-IRI/LV5-FU versus paclitaxel as second-line therapy in patients with metastatic esophageal squamous cell carcinoma (PRODIGE 62-FFCD 1701-OESIRI) Open
PRODIGE 62-OESIRI trial showed low efficacy of paclitaxel and 5FU Nal-IRI in the 2nd line treatment of mESCC, though paclitaxel provided a better safety profile. Trial registration NCT03719924.
View article: Health-related quality of life of Multiple Endocrine Neoplasia Type 1 patients: A mixed methods systematic review
Health-related quality of life of Multiple Endocrine Neoplasia Type 1 patients: A mixed methods systematic review Open
This systematic literature review aimed at gathering available datareporting Quality of Life (QoL) in patients with Multiple Endocrine Neoplasia type 1 (MEN1) in order to identify the determinants of QoL for people living with this conditi…
View article: The impact of cancer survivors’ extra risk of noncancer mortality on net survival estimation
The impact of cancer survivors’ extra risk of noncancer mortality on net survival estimation Open
Relative survival (RS) with the general population as the reference is commonly used to estimate net survival (NS). However, cancer patients may face an increased risk of noncancer death compared to cancer-free individuals. We evaluate the…
View article: Impact of concomitant medication on recurrence, survival and tolerability of chemotherapy in early colon cancer patients – A post-hoc analysis of the PETACC 8 trial
Impact of concomitant medication on recurrence, survival and tolerability of chemotherapy in early colon cancer patients – A post-hoc analysis of the PETACC 8 trial Open
Early CC patients with polypharmacy do not generally exhibit an impaired outcome. Anticoagulation was the only CM category associated with a shorter DFS and OS which might be a consequence of enhanced toxicities necessitating treatment ada…
View article: 104P Deep learning-based automated prognostic stratification through analysis of invasive margin T-cell infiltrates in localized colon cancer
104P Deep learning-based automated prognostic stratification through analysis of invasive margin T-cell infiltrates in localized colon cancer Open
View article: Impact of Lean Body Mass–Based Oxaliplatin Dose Calculation on Neurotoxicity in Adjuvant Treatment of Stage III Colon Cancer: Results of the Phase II Randomized LEANOX Trial
Impact of Lean Body Mass–Based Oxaliplatin Dose Calculation on Neurotoxicity in Adjuvant Treatment of Stage III Colon Cancer: Results of the Phase II Randomized LEANOX Trial Open
PURPOSE Oxaliplatin-based adjuvant chemotherapy is used for stage III colon cancer, but may induce disabling neurotoxicity. We previously showed that the incidence of oxaliplatin-induced peripheral neurotoxicity (OIPN) is higher for oxalip…
View article: Circulating tumor DNA strongly predicts efficacy of chemotherapy plus immune checkpoint inhibitors in patients with advanced gastro-esophageal adenocarcinoma
Circulating tumor DNA strongly predicts efficacy of chemotherapy plus immune checkpoint inhibitors in patients with advanced gastro-esophageal adenocarcinoma Open
An early decrease in ctDNA concentration is a strong predictor of the therapeutic efficacy of ICI plus chemotherapy in advanced gastric/GEJ adenocarcinoma. Clinical Trial Information NCT03959293 (DURIGAST).
View article: A Randomized clinical trial evaluating the impact on survival and quality of life of 177Lutetium[Lu]-edotreotide versus everolimus in patients with neuroendocrine tumors of the lung and thymus: the LEVEL study (GETNE T-2217)
A Randomized clinical trial evaluating the impact on survival and quality of life of 177Lutetium[Lu]-edotreotide versus everolimus in patients with neuroendocrine tumors of the lung and thymus: the LEVEL study (GETNE T-2217) Open
gov : NCT05918302 (June 23rd, 2023).
View article: What are the outcomes for long-term survivors after esophagectomy ? – Evidence from a randomized controlled trial (FFCD9901)
What are the outcomes for long-term survivors after esophagectomy ? – Evidence from a randomized controlled trial (FFCD9901) Open
Being alive 5 years after esophagectomy does not equate to cure. In clinically staged early disease, a distinct group of patients develop disease recurrence later than 5 years from treatment. Development of a second primary cancer in this …
View article: Bevacizumab-based chemotherapy adaptive to pharmacokinetic of bevacizumab in first-line treatment of patients with unresectable metastatic colorectal cancer: A double-blind, multicenter, randomized phase III trial study (PHARBEVACOL trial)
Bevacizumab-based chemotherapy adaptive to pharmacokinetic of bevacizumab in first-line treatment of patients with unresectable metastatic colorectal cancer: A double-blind, multicenter, randomized phase III trial study (PHARBEVACOL trial) Open
Bevacizumab shows inter-individual pharmacokinetic variability, with an exposure-response relationship in metastatic colorectal cancer (mCRC) patients. This study explores whether a double dose of bevacizumab, compared to a standard dose, …
View article: Prognostic Models From Transcriptomic Signatures of the Tumor Microenvironment and Cell Cycle in Stage III Colon Cancer From PETACC-8 and IDEA-France Trials
Prognostic Models From Transcriptomic Signatures of the Tumor Microenvironment and Cell Cycle in Stage III Colon Cancer From PETACC-8 and IDEA-France Trials Open
PURPOSE The objective of this work was to establish prognostic models in stage III colon cancer (CC) on the basis of transcriptomic signatures of the tumor microenvironment (TME) and cell cycle from the PETACC-8 (training set) and IDEA-Fra…
View article: Induction triplet chemotherapy in patients with rectal adenocarcinoma and synchronous metastases, an AGEO-FFCD study
Induction triplet chemotherapy in patients with rectal adenocarcinoma and synchronous metastases, an AGEO-FFCD study Open
The management of metastatic rectal cancer is essentially based on three main therapeutic approaches: surgery, radiotherapy/chemoradiotherapy and chemotherapy. Induction triplet chemotherapy appears as a good choice for fit and young patie…
View article: Phase I/II study of trifluridine/tipiracil plus XB2001 versus trifluridine/tipiracil in metastatic colorectal cancer
Phase I/II study of trifluridine/tipiracil plus XB2001 versus trifluridine/tipiracil in metastatic colorectal cancer Open
Aim: Trifluridine/tipiracil-bevacizumab is a standard of care in metastatic colorectal cancer (mCRC) after chemotherapy failure. We aim to assess the addition of XB2001 (anti-IL-1 alpha monoclonal antibody) plus trifluridine/tipirac…
View article: Genetic and transcriptomic analyses of early-onset colon cancer (EOCC): a post hoc analysis of 2973 patients from two adjuvant randomized trials
Genetic and transcriptomic analyses of early-onset colon cancer (EOCC): a post hoc analysis of 2973 patients from two adjuvant randomized trials Open
Background: Despite decreasing colon cancer (CC) incidence worldwide, an inverse trend is being registered since the late 1990s in people <50 years old, possibly due to an increasing exposure to lifestyle-related risk factors/exposome. Ear…
View article: Circulating tumor DNA strongly predicts efficacy of chemotherapy plus immune checkpoint inhibitors in patients with advanced gastro-esophageal adenocarcinoma
Circulating tumor DNA strongly predicts efficacy of chemotherapy plus immune checkpoint inhibitors in patients with advanced gastro-esophageal adenocarcinoma Open
Efficacy of 2nd line treatment in advanced gastric or gastro-esophageal junction (GEJ) adenocarcinoma remains limited with no identified strong predictor of treatment efficacy. We evaluated the prognostic value of circulating tumor DNA (ct…
View article: Thérapies ciblées et immunothérapie : positionnement dans le champ de l’innovation et enjeux pour le processus de décision thérapeutique
Thérapies ciblées et immunothérapie : positionnement dans le champ de l’innovation et enjeux pour le processus de décision thérapeutique Open
The better understanding of the molecular, cellular, and immunological mechanisms of cancer has led to the development of targeted therapies, then immunotherapy, which have changed the approach to cancer treatment. While these treatments d…
View article: Trends in incidence of infrequent and frequent synchronous metastases from colorectal cancer
Trends in incidence of infrequent and frequent synchronous metastases from colorectal cancer Open
This study provides unprecedented incidence indicators for rare synchronous metastases of colorectal cancer.
View article: How to Balance Prognostic Factors in Controlled Phase II Trials: Stratified Permuted Block Randomization or Minimization? An Analysis of Clinical Trials in Digestive Oncology
How to Balance Prognostic Factors in Controlled Phase II Trials: Stratified Permuted Block Randomization or Minimization? An Analysis of Clinical Trials in Digestive Oncology Open
In controlled phase II trials, major prognostic factors need to be well balanced between arms. The main procedures used are SPBR (Stratified Permuted Block Randomization) and minimization. First, we provide a systematic review of the treat…
View article: Machine learning evaluation of immune infiltrate through digital tumour score allows prediction of survival outcome in a pooled analysis of three international stage III colon cancer cohorts
Machine learning evaluation of immune infiltrate through digital tumour score allows prediction of survival outcome in a pooled analysis of three international stage III colon cancer cohorts Open
This research received no external funding.
View article: Neoadjuvant radiotherapy combined with fluorouracil-cisplatin plus cetuximab in operable, locally advanced esophageal carcinoma: Results of a phase I-II trial (FFCD-0505/PRODIGE-3)
Neoadjuvant radiotherapy combined with fluorouracil-cisplatin plus cetuximab in operable, locally advanced esophageal carcinoma: Results of a phase I-II trial (FFCD-0505/PRODIGE-3) Open
This trial was registered with EudraCT number 2006-004770-27.
View article: Interference With VIP to Distinguish Between Real and False VIPoma: National Study From the French Endocrine Tumors Group
Interference With VIP to Distinguish Between Real and False VIPoma: National Study From the French Endocrine Tumors Group Open
Background Vasoactive intestinal peptide (VIP)-secreting tumors (VIPomas) are digestive neuroendocrine tumors in which the hormonal secretion is life-threatening. Biological confirmation is obtained by demonstrating an elevation in plasma …
View article: Clinico-biological factors predicting the benefit of the LV5FU2 maintenance strategy as a first-line therapy in patients with metastatic pancreatic cancer
Clinico-biological factors predicting the benefit of the LV5FU2 maintenance strategy as a first-line therapy in patients with metastatic pancreatic cancer Open
Introduction Predictive markers of LV5FU2 maintenance benefit after first-line induction with FOLFIRINOX in patients with metastatic pancreatic cancer are necessary to select patients who will not be harmed by this strategy. Patients and M…
View article: First-Line LV5FU2 with or without Aflibercept in Patients with Non-Resectable Metastatic Colorectal Cancer: A Randomized Phase II Trial (PRODIGE 25-FFCD-FOLFA)
First-Line LV5FU2 with or without Aflibercept in Patients with Non-Resectable Metastatic Colorectal Cancer: A Randomized Phase II Trial (PRODIGE 25-FFCD-FOLFA) Open
Fluropyrimidine monotherapy is an option for some patients with inoperable metastatic colorectal cancer. Unlike bevacizumab, the addition of aflibercept, an antibody acting as an anti-angiogenic agent, has never been evaluated in this cont…
View article: FOLFIRI Plus Durvalumab With or Without Tremelimumab in Second-Line Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
FOLFIRI Plus Durvalumab With or Without Tremelimumab in Second-Line Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Open
Importance Efficacy of second-line chemotherapy in advanced gastric or gastrooesphageal junction (GEJ) adenocarcinoma remains limited. Ojectives To determine the efficacy of 1 or 2 immune checkpoint inhibitors combined with FOLFIRI (leucov…
View article: 629P First results of the french prospective cohort of colorectal cancers with microsatellite instability (COLOMIN2)
629P First results of the french prospective cohort of colorectal cancers with microsatellite instability (COLOMIN2) Open
View article: 731P REWENEC: REal-World Evidence in NEC provides a reliable external control arm to avoid randomization for second-line clinical trials - A post hoc proof of concept analysis with the randomized phase II BEVANEC study
731P REWENEC: REal-World Evidence in NEC provides a reliable external control arm to avoid randomization for second-line clinical trials - A post hoc proof of concept analysis with the randomized phase II BEVANEC study Open
View article: LBA77 5-fluorouracil and oxaliplatin with or without docetaxel in the first-line treatment of HER2 negative locally advanced (LA) unresectable or metastatic gastric or gastro-esophageal junction (GEJ) adenocarcinoma (GASTFOX-PRODIGE 51): A randomized phase III trial sponsored by the FFCD
LBA77 5-fluorouracil and oxaliplatin with or without docetaxel in the first-line treatment of HER2 negative locally advanced (LA) unresectable or metastatic gastric or gastro-esophageal junction (GEJ) adenocarcinoma (GASTFOX-PRODIGE 51): A randomized phase III trial sponsored by the FFCD Open